Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Endocrine/metabolic disease

Mitochondrial disease

Pyruvate dehydrogenase kinase (PDK)

In vitro and in vivo studies suggest phenylbutyrate could help treat mitochondrial pyruvate dehydrogenase complex (PDHC) deficiency, the most common genetic form of lactic acidosis. In enzymatic assays, phenylbutyrate bound PDK to prevent inactivation of PDHC. In 9 of 15 patient-derived, PDHC-deficient fibroblast cell lines, phenylbutyrate increased PDHC activity compared with no treatment. In zebrafish and mouse models for lactic acidosis, phenylbutyrate decreased lactate levels compared with no treatment. Next steps include designing a clinical trial for patients with PDHC deficiency.
Valeant Pharmaceuticals International Inc. and Hyperion Therapeutics Inc. market Ravicti glycerol phenylbutyrate to treat urea cycle disorder. The compound is in Phase II testing to treat liver disease.

SciBX 6(10); doi:10.1038/scibx.2013.240
Published online March 14, 2013

Unpatented; unlicensed

Ferriero, R. et al. Sci. Transl. Med.; published online March 6, 2013;
doi:10.1126/scitranslmed.3004986
Contact: Nicola Brunetti-Pierri, Telethon Institute of Genetics and Medicine, Naples, Italy
e-mail:
brunetti@tigem.it